We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanom... Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others. Show more
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Rodney Cotton has been appointed to its board of...
Company honored for creating an exceptional, people-first culture that empowers employees and fosters trust, transparency and authenticity Castle Biosciences, Inc. (Nasdaq: CSTL), a company...
Castle’s second presentation at SSO 2024 shows that in a study of 979 patients, DecisionDx-Melanoma demonstrated clinical use value in patients with TI cutaneous melanoma (CM), identifying...
The consensus guidelines were drafted by a multidisciplinary panel of radiation oncologists and dermatologists/Mohs micrographic surgeons with expertise in cutaneous squamous cell carcinoma (SCC...
Study data show that one-third of the IDgenetix-guided medication recommendations were due to drug-drug interactions and lifestyle factors, demonstrating the value of this additional information...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to...
Castle’s presentations at AAD include the latest findings from the Company’s ongoing collaboration with the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program...
Largest study of gene expression profile testing in patients with high-risk cutaneous squamous cell carcinoma (SCC) supports test’s ability to provide clinically actionable risk stratification to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.63 | 7.94346978558 | 20.52 | 22.52 | 20.12 | 206371 | 21.02196187 | CS |
4 | -2.7 | -10.8651911469 | 24.85 | 24.8739 | 17.42 | 314149 | 20.15866928 | CS |
12 | 1.32 | 6.33701392223 | 20.83 | 25.6 | 17.42 | 257948 | 21.56573816 | CS |
26 | 5.74 | 34.9786715417 | 16.41 | 25.6 | 12.07 | 263517 | 19.27411793 | CS |
52 | -0.27 | -1.20428189117 | 22.42 | 26.7 | 9.2601 | 384918 | 17.87131283 | CS |
156 | -37.04 | -62.578138199 | 59.19 | 78.92 | 9.2601 | 283563 | 29.77077299 | CS |
260 | 2.15 | 10.75 | 20 | 107.69 | 9.2601 | 254647 | 34.67955528 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions